Asset Management One Co. Ltd. Increases Stock Position in Boston Scientific Corporation $BSX

Key Points

• Asset Management One increased its stake in Boston Scientific by 13.3% in Q4, buying 103,326 shares to hold 879,105 shares worth about $84.13 million (≈0.06% of the company).
• Market momentum is positive: analysts are increasingly bullish (citing ~30% year‑over‑year growth expectations for 2026), Boston Scientific beat Q4 EPS estimates ($0.80 vs. $0.78) with revenue up 15.9% YoY, and the company is investing $88.4 million to expand R&D in Ireland.
• Near‑term risks include multiple class‑action filings alleging securities violations for the July 23, 2025–Feb 3, 2026 period (lead‑plaintiff solicitation with a May 4 deadline) and notable insider selling by CEO Michael F. Mahoney, who sold 160,901 shares (a 10.23% reduction in his holdings).

Asset Management One Co. Ltd. lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 879,105 shares of the medical equipment provider's stock after purchasing an additional 103,326 shares during the quarter. Asset Management One Co. Ltd. owned about 0.06% of Boston Scientific worth $84,134,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in BSX. Crown Wealth Group LLC raised its holdings in Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider's stock worth $218,000 after purchasing an additional 100 shares in the last quarter. Claret Asset Management Corp raised its stake in Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider's stock valued at $234,000 after purchasing an additional 102 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its stake in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider's stock valued at $206,000 after acquiring an additional 103 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors increased its position in Boston Scientific by 2.3% during the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider's stock worth $466,000 after purchasing an additional 108 shares in the last quarter. Finally, Kera Capital Partners Inc. boosted its holdings in Boston Scientific by 3.3% in the 3rd quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider's stock worth $333,000 after acquiring an additional 109 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts are increasingly bullish, citing expectations for ~30% year‑over‑year growth in 2026 and constructive analyst commentary that supports upside to BSX’s earnings trajectory. Analysts Bullish on Boston Scientific (BSX)
• Positive Sentiment: Zacks previews point to robust cardiovascular momentum and steady MedSurg growth heading into Q1 results, implying potential upside to revenue and EPS vs. consensus if procedure trends hold. Will Robust Cardiovascular Performance Fuel BSX's Q1 Earnings?
• Positive Sentiment: Boston Scientific is investing $88.4M to expand R&D operations in Ireland — a sign of continued product development and investment in innovation that supports medium‑term growth prospects. Boston Scientific invests $88.4M to expand R&D in Ireland
• Neutral Sentiment: Zacks also published a deeper Q1 preview on key operational metrics investors should watch (procedure volumes, segment mix, product cadence) that could swing reactions to the print beyond headline revenue/EPS. Boston Scientific (BSX) Q1 Earnings Preview
• Neutral Sentiment: Recent pieces revisiting BSX’s valuation and the impact of the Penumbra acquisition provide context on multiples and longer‑term returns; useful for investors framing position sizing but less likely to move intraday trading. A Look At Boston Scientific (BSX) Valuation
• Negative Sentiment: Multiple law firms have issued investor alerts and a class action has been filed alleging securities‑law violations for the July 23, 2025–Feb 3, 2026 period. These coordinated filings and lead‑plaintiff solicitations (with a May 4 deadline cited by several firms) are a near‑term headline risk that can pressure the stock or increase legal expenses/uncertainty. Representative notices and filings: PR Newswire: Shareholders Opportunity to Lead Securities Fraud Lawsuit Bronstein, Gewirtz & Grossman Class Action Notice Faruqi & Faruqi Deadline Reminder

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. Weiss Ratings cut Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, February 4th. Robert W. Baird decreased their price target on Boston Scientific from $118.00 to $101.00 and set an "outperform" rating for the company in a research report on Thursday, February 5th. Barclays cut their price target on Boston Scientific from $136.00 to $124.00 and set an "overweight" rating for the company in a research note on Tuesday, February 3rd. Stifel Nicolaus cut their price objective on Boston Scientific from $110.00 to $90.00 and set a "buy" rating on the stock in a research note on Friday, March 20th. Finally, Wells Fargo & Company lowered their price objective on Boston Scientific from $125.00 to $94.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $102.82.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.34% of the company's stock.

Boston Scientific Stock Performance

BSX opened at $64.28 on Friday. Boston Scientific Corporation has a 52-week low of $60.59 and a 52-week high of $109.50. The firm has a market capitalization of $95.53 billion, a PE ratio of 33.13, a PEG ratio of 0.98 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The business's 50-day simple moving average is $69.60 and its 200 day simple moving average is $86.96.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific's revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.